Simon S. Jones

Simon S. Jones, Ph.D., is the President and Chief Executive Officer of Regenacy Pharmaceuticals and served as Chief Operating Officer and Senior Vice President of Preclinical Development, from the formation of Regenacy in December 2016. Simon joined Acetylon in September 2009 from EPIX Pharmaceuticals Inc., where he was Vice President of Biology and ADMET. Prior to EPIX, Dr. Jones held senior level positions in drug discovery and preclinical development for leading biotechnology companies including ArQule Inc., Curis Inc., Creative BioMolecules Inc. and at Genetics Institute/Wyeth, now part of Pfizer. Dr. Jones received his B.Sc. Honors Degree and Ph.D. in chemistry from Kings College, University of London, U.K., where he also engaged in post-doctoral research, and later at the Massachusetts Institute of Technology, Cambridge, MA under the Nobel Laureate Prof. H.G. Khorana.